Biohaven (BHVN) Debt Ratio (2025 - 2026)
Biohaven (BHVN) reported Debt Ratio of 0.52 for Q1 2026, down 1.99% sequentially from 0.53 in Q4 2025.
Biohaven (BHVN) Debt Ratio (2025 - 2026) Analysis & Trends
Biohaven (BHVN) has 2 years of Debt Ratio data on file, last reported at 0.52 in Q1 2026.
- For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.52; the trailing twelve-month figure through Mar 2026 stood at 0.52 (changed N/A YoY), and the FY2025 full-year result was 0.53, changed N/A from the prior year.
- Debt Ratio declined to 0.52 in Q1 2026, from 0.53 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.66 in Q3 2025 to a low of 0.47 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | 0.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.52 |
| Dec 31, 2025 | 0.53 |
| Sep 30, 2025 | 0.66 |
| Jun 30, 2025 | 0.47 |